Created by specialists at the Center for Molecular Immunology (CIM) in Havana during 25 years of research, Cimavax-EGF therapeutical vaccine against small cells advanced lung cancer have been applied in more than 5000 patients with promising results.
The Therapeutic Vaccine for Lung Cancer is a drug that is applied to patients in stages IIIb and IV to increase their survival.
Most of us are familiar with the use of vaccines to combat certain diseases such as the flu, chicken pox, or measles vaccine. However, the use of therapeutic cancer vaccines may not be a common term. Advances in research and improved diagnostics are enabling the development of a new generation of drugs for treating tumors. Among these new drugs to fight cancer, treatments based on immunotherapies, are offering very promising results.
Therapeutic vaccines use the same mechanism as preventive vaccines, except that their action is to cure or decrease the patient's disease state, increasing their survival through the activation of their immune system.
The basic idea is to mobilize the immune system so that its components, which normally defend you against all kinds of diseases, fight against cancer cells that grow inside the body.
The vaccines for lung cancer CIMAvax-EGFhr and Vaxira offer the possibility of turning advanced cancer into a controllable chronic disease, as it generates antibodies against proteins that trigger uncontrolled cell proliferation processes.
The action of the treatment of vaccines for lung cancer is based on active immunotherapy; that is, it manipulates the immune response of an individual so that it generates its own antibodies.
It is important to note that the vaccine does not prevent the disease like a traditional vaccine; its action is to prevent lung cancer tumors from developing further, acting more as a treatment. It is known, therefore, as a therapeutic vaccine. Rather than targeting cancer cells directly, the vaccine acts as a form of immunotherapy.
It is not a curative drug, but it stabilizes the tumor and leads the disease to chronic non-communicable pathology.
Treatment for lung cancer with the CIMAvax-EGFhr or Vaxira vaccines is indicated in those patients who meet certain requirements or conditions such as:
1. Patient is older than 18 years old
2. Carriers of non-small cell lung tumors.
3. Patients in advanced stages of the disease (IIIb and IV).
4. To have completed the first line of oncospecific therapy.
5. That the tumor has originated in the lung.
6. The tumor must not have metastasized to the brain.
7. Others
Consult other requirements or conditions to opt for this vaccine
IMPORTANT
IN ORDER TO HAVE A QUICK AND EFFECTIVE RESPONSE, WE RECOMMEND TO READ CAREFULLY THE REQUIREMENTS FOR THE PATIENT TO BE ACCEPTED AND MAKE SURE THAT THE PATIENT MEETS THEM. ALSO, DO NOT LIMIT YOURSELF TO CONTACT US EVEN IF THE PATIENT DOES NOT MEET SOME OF THE REQUIREMENTS, WE COULD RECOMMEND A TREATMENT OPTION TO IMPROVE THE QUALITY OF LIFE IN CASE THE PATIENT IS NOT A CANDIDATE FOR TREATMENT WITH THE THERAPEUTIC VACCINE FOR LUNG CANCER.
It is not necessary for the patient to travel to seek treatment, a family member or friend can do it, but first it is essential to send all the evaluation they have and that the medical team approve their application.
THE MEDICATION DURING THE TRIP TO YOUR COUNTRY MUST BE KEPT COLD, SO WE SUGGEST YOU BRING A THERMAL BAG AND GEL TO FREEZE.
Previously, the patient must give their consent in writing
We recommend that the patient avoid touching, massaging or scratching the area.
CimaVax-EFG® is a vaccine composed of EFG conjugated with a carrier protein (carrier) and an adjuvant (Montanide ISA51). This vaccine induces the manufacture of antibodies that bind to the EFG receptor (EFG-R), making the interaction [EFG EFG-R] impossible and in this way the tumor is considerably reduced.
Racotumomab (Vaxira) is an IG1 isotype murine anti-idiotic monoclonal antibody raised against Mab P3. It recognizes mAb P3 and specifically inhibits its binding to N-glycolylated gangliosides, in particular to the NeuGcGM3 ganglioside, which is a tumor-specific antigen. The NeuGcGM3 ganglioside is expressed in different types of tumor cells.
Immunization of patients with non-small cell lung tumors (NSCLC) with the VAXIRA® vaccine induces the production of IgG and IgM isotype-specific Ab3 antibodies against the NeuGcGM3 ganglioside, capable of recognizing this antigen and causing the lysate. of the tumor surface (antibodies with cytotoxic capacity).
Although both vaccines for lung cancer have the same indication, their mechanisms of action are different: CIMAvax EGF arrests circulating EGF - epidermal growth factor - in blood and VAXIRA acts on a specific tumor antigen called Nglycolylated ganglioside - NGcM3, through of an immune network of idiotypes. These are different mechanisms on which drugs targeting EGFR mutations, or ALK alterations, act.
id="8"
.jpg)
.jpg)
